The Biostatistics and Data Management Core (BDMC) provides a central resource to the ADCS consortium for biostatistical expertise in the design, management and analysis of Alzheimer's disease clinical trials and state-of-the-art data management of these trials. The BDMC further oversees a comprehensive quality assurance program covering the spectrum of ADCS activities. The biostatistical responsibilities of the BDMC include: providing input into the experimental design of each protocol, with emphasis on the power analysis and the assessment of reliability and validity of measurement instruments; developing and generating the randomization sequences for each trial; performing preliminary and final statistical analyses on trial results; assisting in the preparation of reports and publications; developing new statistical methodology, as needed, and serving as a general biostatistical resource for investigators in the consortium. All ADCS clinical trial data is managed through the BDMC. Every aspect of the data collection process, including forms design and printing, maintaining centralized patient files, and generate special purpose and routine statistical reports on accumulating data, is coordinated through the data management operation of the BDMC. The BDMC data environment is sophisticated. Approximately 15 PC workstations are connected in a client-server architecture, using a Novell Netware local area network (LAN). Data management is conducted through the ORACLE relational database management system. The Quality Assurance program of the BDMC is extensive. At its center is the clinical and computerized monitoring of the data, but it extends to cover training, document (training manuals, manuals of operation, newsletters, etc.) and instrument development, and archiving of regulatory documents. The BDMC coordinates a clinical monitoring program through which all ADCS data forms are reviewed on-site by highly trained clinical monitors prior to inclusion in the centralized database. Computerized edit checking is done both at the time of entry, and longitudinally. A systematic audit of the database (proposed) will compare physical case report forms with their electronic images.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AG010483-10
Application #
6315223
Study Section
Project Start
2000-07-01
Project End
2001-09-14
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
10
Fiscal Year
2000
Total Cost
$228,404
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Chen, Yun-Fei; Ni, Xiao; Fleisher, Adam S et al. (2018) A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimers Dement (N Y) 4:46-53
Rockenstein, Edward; Ostroff, Gary; Dikengil, Fusun et al. (2018) Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies. J Neurosci 38:1000-1014
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535
Moussa, Charbel; Hebron, Michaeline; Huang, Xu et al. (2017) Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation 14:1
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
El-Agnaf, Omar; Overk, Cassia; Rockenstein, Edward et al. (2017) Differential effects of immunotherapy with antibodies targeting ?-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiol Dis 104:85-96
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Tarrant, Sarah D; Bardach, Shoshana H; Bates, Kendra et al. (2017) The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord 31:141-145
Kennedy, Richard E; Cutter, Gary R; Wang, Guoqiao et al. (2017) Challenging Assumptions About African American Participation in Alzheimer Disease Trials. Am J Geriatr Psychiatry 25:1150-1159

Showing the most recent 10 out of 294 publications